1-6 of 6
Christine White
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Depletion of the Mitochondrial E3 Ligase MARCH5 Induces Synthetic Lethality to BCL2 Inhibitor (Venetoclax) Therapy in Cell Lines Representative of Diverse Blood Cancers

Thomas E Lew, Mark Van Delft, Chris Riffkin, Georgiou Angela, Christine White, Yin Yuan, Jahja Michelle, Mary Ann Anderson, Rachel Thijssen, David C.S. Huang, Mark A Dawson, Andrew W. Roberts
Journal: Blood
Blood (2023) 142 (Supplement 1): 415.
https://doi.org/10.1182/blood-2023-184392
Published: 2023
Journal Articles

NF-κB1 and c-Rel cooperate to promote the survival of TLR4-activated B cells by neutralizing Bim via distinct mechanisms

Ashish Banerjee, Raelene Grumont, Raffi Gugasyan, Christine White, Andreas Strasser, Steve Gerondakis
Journal: Blood
Blood (2008) 112 (13): 5063–5073.
https://doi.org/10.1182/blood-2007-10-120832
Published: 2008
Includes: Supplemental data
Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90 YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

Jane N. Winter, MD, David Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, B.S., William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Andrew Evens, D.O., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.
Journal: Blood
Blood (2006) 108 (11): 330.
https://doi.org/10.1182/blood.V108.11.330.330
Published: 2006
Journal Articles

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Clinical Trials & Observations
Auayporn Nademanee, Stephen Forman, Arturo Molina, Henry Fung, David Smith, Andy Dagis, Cheuk Kwok, Dave Yamauchi, Anne-Line Anderson, Peter Falk, Amrita Krishnan, Mark Kirschbaum, Neil Kogut, Ryotaro Nakamura, Margaret O'Donnell, Pablo Parker, Leslie Popplewell, Vinod Pullarkat, Roberto Rodriguez, Firoozeh Sahebi, Eileen Smith, David Snyder, Anthony Stein, Ricardo Spielberger, Jasmine Zain, Christine White, Andrew Raubitschek
Journal: Blood
Blood (2005) 106 (8): 2896–2902.
https://doi.org/10.1182/blood-2005-03-1310
Published: 2005
Journal Articles

Incidence of Altered Biodistribution Detected by Indium 111 ( 111 In) Imaging Prior to Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy: Results from a Zevalin Imaging Registry.

Peter Conti, MD, Christine White, MD, Peter Pieslor, MD, Gene Menendez, V. Douglas Harrough, MS, MBA, Dan Matso, PharmD, Jacqueline Aussie, Thomas Ryskamp, Paul A. Foster, MD
Journal: Blood
Blood (2004) 104 (11): 4570.
https://doi.org/10.1182/blood.V104.11.4570.4570
Published: 2004
Journal Articles

90 Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Higher Than .4 mCi/kg May Be Safely Combined with High-Dose Beam and Autotransplant: The Role for Dosimetry.

Jane N. Winter, M.D., David J. Inwards, M.D., Stewart Spies, M.D., Gregory Wiseman, M.D., David Patton, William Erwin, M.S., Alfred Rademaker, Ph.D., Stephanie F. Williams, M.D., Martin S. Tallman, M.D., Ivana Micallef, M.D., Jayesh Mehta, M.D., Seema Singhal, M.D., Michael Zimmer, Ph.D., Arturo Molina, M.D., Christine White, M.D., Leo I. Gordon, M.D.
Journal: Blood
Blood (2004) 104 (11): 1162.
https://doi.org/10.1182/blood.V104.11.1162.1162
Published: 2004